Exodus Point Capital Management, LP Larimar Therapeutics, Inc. Transaction History
Exodus Point Capital Management, LP
- $16.4 Billion
- Q3 2024
A detailed history of Exodus Point Capital Management, LP transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 21,119 shares of LRMR stock, worth $131,571. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,119Holding current value
$131,571% of portfolio
0.0%Shares
4 transactions
Others Institutions Holding LRMR
# of Institutions
128Shares Held
67.3MCall Options Held
280KPut Options Held
76.3K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$132 Million2.59% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$37.7 Million0.55% of portfolio
-
Janus Henderson Group PLC London, X05.57MShares$34.7 Million0.02% of portfolio
-
Goldman Sachs Group Inc New York, NY4.25MShares$26.5 Million0.0% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.17MShares$26 Million9.0% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $270M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...